GlassScriptPhysician profile
Jeffrey T Jenkins
NPI 1396189437
$6,611.68
in general payments reported to CMS, 2019-2025
29 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $832 · 2021: $983 · 2022: $1,094 · 2023: $1,241 · 2024: $940 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,452.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $476.42 | 2020-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.25 | 2019-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $388.93 | 2022-2024 | |
| Genzyme Corporation | $358.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $357.36 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $302.52 | 2019-2024 | Airsupra, Fasenra |
| Genentech USA, INC. | $286.31 | 2019-2024 | Xolair |
| Mylan Specialty L.P. | $255.86 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $183.06 | 2022-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $142.47 | 2021-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $119.81 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $118.20 | 2021-2022 | |
| Amgen INC. | $98.38 | 2023-2025 | Tezspire |
| Circassia INC. | $97.68 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $87.35 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $66.96 | 2022 | |
| Philips North America LLC | $59.75 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $50.24 | 2020-2023 | Nuzyra |
| Axsome Therapeutics, INC. | $46.69 | 2023 | Sunosi |
| Shire North American Group INC | $34.86 | 2019 | |
| Medical Graphics Corporation | $34.37 | 2020 | |
| Inspire Medical Systems, INC. | $26.51 | 2023 | Inspire |
| Mallinckrodt Hospital Products INC. | $18.85 | 2023 | Acthar |
| Allergan, INC. | $18.07 | 2019 | |
| Verona Pharma, INC. | $17.63 | 2025 | Ohtuvayre |
| Abbvie INC. | $16.82 | 2023 | |
| Inogen, INC. | $16.29 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Phadia US INC. | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.